Fungal Prophylaxis With Isavuconazole for Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HCT)
The purpose of this study is to study the effects of isavuconazole in preventing fungal infections in patients who have had a hematopoietic stem cell transplant (HCT).
Hematologic Malignancy|Myeloproliferative Disorder
DRUG: Isavuconazole
Clinical Failure of Isavuconazole Prophylaxis by Week + 14 Post Hematopoietic Stem Cell Transplant (HCT), Clinical failure is measured by:

1. Systemic antifungal therapy for \> 14 consecutive days for suspected fungal infection up to week 14.
2. Breakthrough proven or probable fungal infection during the prophylaxis phase.\*
3. Toxicity leading to permanent discontinuation of prophylaxis
4. Adverse event requiring discontinuation.

   * The prophylaxis phase was defined as the period from the first dose of isavuconazole through 7 days after discontinuation of isavuconazole., 14 weeks post HCT|Clinical Failure of Isavuconazole Prophylaxis by Week + 26 Post Hematopoietic Stem Cell Transplant (HCT), Clinical failure is measured by:

1. Systemic antifungal therapy for \> 14 consecutive days for suspected fungal infection up to week 14.
2. Breakthrough proven or probable fungal infection during the prophylaxis phase.\*
3. Toxicity leading to permanent discontinuation of prophylaxis
4. Adverse event requiring discontinuation.

   * The prophylaxis phase was defined as the period from the first dose of isavuconazole through 7 days after discontinuation of isavuconazole., 26 weeks post HCT
The purpose of this study is to study the effects of isavuconazole in preventing fungal infections in patients who have had a hematopoietic stem cell transplant (HCT).